BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

646 related articles for article (PubMed ID: 26811150)

  • 21. Fecal Immunochemical Test (FIT) for Colon Cancer Screening: Variable Performance with Ambient Temperature.
    Doubeni CA; Jensen CD; Fedewa SA; Quinn VP; Zauber AG; Schottinger JE; Corley DA; Levin TR
    J Am Board Fam Med; 2016 Nov; 29(6):672-681. PubMed ID: 28076249
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple rounds of one sample versus two sample faecal immunochemical test-based colorectal cancer screening: a population-based study.
    Schreuders EH; Grobbee EJ; Nieuwenburg SAV; Kapidzic A; van Roon AHC; van Vuuren AJ; Lansdorp-Vogelaar I; Spijker WWJ; Izelaar K; Bruno MJ; Kuipers EJ; Spaander MCW
    Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):622-631. PubMed ID: 31196734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fecal immunochemical test in cancer screening - colonoscopy outcome in FIT positives and negatives.
    Ribbing Wilén H; Blom J; Höijer J; Andersson G; Löwbeer C; Hultcrantz R
    Scand J Gastroenterol; 2019 Mar; 54(3):303-310. PubMed ID: 30907196
    [No Abstract]   [Full Text] [Related]  

  • 24. Effect of Colonoscopy Outreach vs Fecal Immunochemical Test Outreach on Colorectal Cancer Screening Completion: A Randomized Clinical Trial.
    Singal AG; Gupta S; Skinner CS; Ahn C; Santini NO; Agrawal D; Mayorga CA; Murphy C; Tiro JA; McCallister K; Sanders JM; Bishop WP; Loewen AC; Halm EA
    JAMA; 2017 Sep; 318(9):806-815. PubMed ID: 28873161
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of age- and gender-specific cut-off values for the fecal immunochemical test for hemoglobin in colorectal cancer screening.
    Alvarez-Urturi C; Andreu M; Hernandez C; Perez-Riquelme F; Carballo F; Ono A; Cruzado J; Cubiella J; Hernandez V; Mao CG; Perez E; Salas D; Andrés M; Bujanda L; Portillo I; Sarasqueta C; Quintero E; Morillas JD; Lanas A; Sostres C; Augé JM; Castells A; Bessa X;
    Dig Liver Dis; 2016 May; 48(5):542-551. PubMed ID: 26936343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fecal immunochemical testing results and characteristics of colonic lesions.
    van Doorn SC; Stegeman I; Stroobants AK; Mundt MW; de Wijkerslooth TR; Fockens P; Kuipers EJ; Bossuyt PM; Dekker E
    Endoscopy; 2015 Nov; 47(11):1011-7. PubMed ID: 26126163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contribution of the OC Sensor
    Vitellius C; Laly M; Banaszuk AS; Deherce I; Cornet N; Bertrais S; Saulnier P; Caroli-Bosc FX
    Eur J Epidemiol; 2019 Feb; 34(2):163-172. PubMed ID: 30536183
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Random comparison of repeated faecal immunochemical testing at different intervals for population-based colorectal cancer screening.
    van Roon AH; Goede SL; van Ballegooijen M; van Vuuren AJ; Looman CW; Biermann K; Reijerink JC; Mannetje H'; van der Togt AC; Habbema JD; van Leerdam ME; Kuipers EJ
    Gut; 2013 Mar; 62(3):409-15. PubMed ID: 22387523
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An analysis of the duplicate testing strategy of an Irish immunochemical faecal occult blood test colorectal cancer screening programme.
    Kelley L; Swan N; Hughes DJ
    Colorectal Dis; 2013 Sep; 15(9):e512-21. PubMed ID: 23746062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Age-adapted Variation in Screening Interval of Fecal Immunochemical Test May Improve its Participation and Colonoscopy Acceptance.
    Kwak MS; Cha JM; Yoon JY; Jeon JW; Shin HP; Joo KR; Lee JI
    J Clin Gastroenterol; 2017 Oct; 51(9):825-830. PubMed ID: 27824639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes and cost evaluation of the first two rounds of a colorectal cancer screening program based on immunochemical fecal occult blood test in northern Italy.
    Parente F; Boemo C; Ardizzoia A; Costa M; Carzaniga P; Ilardo A; Moretti R; Cremaschini M; Parente EM; Pirola ME
    Endoscopy; 2013; 45(1):27-34. PubMed ID: 23254404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Veterans' Continued Participation in an Annual Fecal Immunochemical Test Mailing Program for Colorectal Cancer Screening.
    Schlichting JA; Mengeling MA; Makki NM; Malhotra A; Halfdanarson TR; Klutts JS; Levy BT; Kaboli PJ; Charlton ME
    J Am Board Fam Med; 2015; 28(4):494-7. PubMed ID: 26152441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors associated with interval colorectal cancer after negative FIT: Results of two screening rounds in the Dutch FIT-based CRC screening program.
    Breekveldt ECH; Toes-Zoutendijk E; van de Schootbrugge-Vandermeer HJ; de Jonge L; Kooyker AI; Spaander MCW; van Vuuren AJ; van Kemenade FJ; Ramakers C; Dekker E; Nagtegaal ID; van Leerdam ME; Lansdorp-Vogelaar I
    Int J Cancer; 2023 Apr; 152(8):1536-1546. PubMed ID: 36444504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of Increasing Screening Age and Fecal Hemoglobin Cutoff Concentrations in a Colorectal Cancer Screening Program.
    Wieten E; Schreuders EH; Nieuwenburg SA; Hansen BE; Lansdorp-Vogelaar I; Kuipers EJ; Bruno MJ; Spaander MC
    Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1771-1777. PubMed ID: 27567693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunochemical faecal occult blood testing to screen for colorectal cancer: can the screening interval be extended?
    Haug U; Grobbee EJ; Lansdorp-Vogelaar I; Spaander MCW; Kuipers EJ
    Gut; 2017 Jul; 66(7):1262-1267. PubMed ID: 27006184
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia.
    de Wijkerslooth TR; Stoop EM; Bossuyt PM; Meijer GA; van Ballegooijen M; van Roon AH; Stegeman I; Kraaijenhagen RA; Fockens P; van Leerdam ME; Dekker E; Kuipers EJ
    Am J Gastroenterol; 2012 Oct; 107(10):1570-8. PubMed ID: 22850431
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Program Components and Results From an Organized Colorectal Cancer Screening Program Using Annual Fecal Immunochemical Testing.
    Selby K; Jensen CD; Levin TR; Lee JK; Schottinger JE; Zhao WK; Corley DA; Doubeni CA
    Clin Gastroenterol Hepatol; 2022 Jan; 20(1):145-152. PubMed ID: 33010408
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gender Differences in Fecal Immunochemical Test Performance for Early Detection of Colorectal Neoplasia.
    Kapidzic A; van der Meulen MP; Hol L; van Roon AH; Looman CW; Lansdorp-Vogelaar I; van Ballegooijen M; van Vuuren AJ; Reijerink JC; van Leerdam ME; Kuipers EJ
    Clin Gastroenterol Hepatol; 2015 Aug; 13(8):1464-71.e4. PubMed ID: 25724706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Colonoscopy vs. Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM): Rationale for Study Design.
    Dominitz JA; Robertson DJ; Ahnen DJ; Allison JE; Antonelli M; Boardman KD; Ciarleglio M; Del Curto BJ; Huang GD; Imperiale TF; Larson MF; Lieberman D; O'Connor T; O'Leary TJ; Peduzzi P; Provenzale D; Shaukat A; Sultan S; Voorhees A; Wallace R; Guarino PD
    Am J Gastroenterol; 2017 Nov; 112(11):1736-1746. PubMed ID: 29016565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors associated with false-positive and false-negative fecal immunochemical test results for colorectal cancer screening.
    Wong MC; Ching JY; Chan VC; Lam TY; Luk AK; Ng SS; Sung JJ
    Gastrointest Endosc; 2015 Mar; 81(3):596-607. PubMed ID: 25293827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.